Ingen Technologies, Inc.
35193 Avenue “A”
Suite-C
Yucaipa, CA 92399
United States
Phone: 800-259-9622
www.ingen-tech.com
Ingen Technologies, Inc., a medical device manufacturer, engages in the development, marketing, and distribution of medical technologies and products with applications in the respiratory device markets and the medical diagnostics market, as well as in emergency response, aviation, military and consumer markets. Products Ingen Technologies manufactures the medical devices Oxyview and OxyAlert, which are products designed for the respiratory patient market in the USA and abroad. Oxyview and OxyAlert provide the respiratory clinicians, including pulmonologists, respiratory therapists and patient care technicians a medical product that provides assurance and safety to home oxygen patients and hospitalized patients while monitoring oxygen flow during oxygen therapy. Patients using portable oxygen concentrators, home oxygen concentrators, liquid oxygen and oxygen gas can use Oxyview and OxyAlert to improve their oxygen delivery. Oxyview is a Class-I medical device as classified with the US Food and Drug Administration as an in-line oxygen flow meter that is powered by the flow of oxygen and requires no batteries. Oxyview provides a visual cue to the patient or administrator, indicating the continuous flow and volume of oxygen during therapy. It allows the user to be sure that they are receiving the proper oxygen level and alerts them if adjustments need to be made. This device would simplify the oxygen therapy process. Oxyview is reusable, requires no batteries, works all the time in any position with all liquid or gas oxygen delivery systems, and installs anywhere below the cannula nearest the patient where oxygen flow matters the most. In addition to Oxyview, the company is set up to begin selling a natural energy drink referred to as PogaMoonga. This product is a natural drink processed from pomegranate, aloe vera and the leaves and seeds of the moringa tree. This product provides oxygen therapy patients, and consumers with a way to naturally increase their energy levels. OxyAlert is a multi-patented wireless digital pressure gauge with hand-remote, and audio/visual safety warning device used on stationary and remote oxygen delivery devices, such as concentrators and cylinders; used by patients, hospitals, commercial aircraft, military transport, and fire and safety equipment. GasAlert is a commercial consumer product using the same technology as OxyAlert. This device would monitor and detect gas flow for home appliances, such as ovens, washer, dryer, refrigerator and outdoor plumbed barbeques. GasAlert uses the same technology as OxyAlert, and its application is directed towards determining gas leaks. GasAlert would be marketed upon the US Food and Drug Administration’s classification and acceptance of OxyAlert. The Secure Balance product is a private-label product that includes a vestibular function testing system and balance therapy system. The vestibular (referencing organs in the inner ear) function testing system is manufactured by Interacoustics LTD. in Denmark and is referred to as the VNG. This is an accepted method among physicians to provide diagnostic testing of the inner-ear and central nervous system, in order to provide qualitative results that determine a diagnosis of a patients balance problem. This system is used to provide therapy to patients with balance problems through the use of computerized clinical software tools. The company’s Secure Balance program provides balance testing/assessment equipment, education and training about balance and fall prevention to physicians and clinicians worldwide. Competition The company’s products compete with the Liter-Meter manufactured by Erie Medical, Inc., and the Rotameter manufactured by King Instruments. History Ingen Technologies, Inc. was founded in 1999.
Why this is a hot stock
- Ingen has interested acquirers according to the Pacific Pearl Group Inc., and company management has agreed to hold the buy-out price of no less than 10 cents a share,” stated Thomas J. Neavitt, Chief Financial Officer.
- On November 18, 2009, Emergo Group will introduce the new Oxyview Nasal Cannula at MEDICA in Germany. MEDICA is the center of attraction for all those involved in the health care industry. More than 135,000 visitors from well over 100 countries are expected to again obtain information on all the current and future trends in in-patient and out-patient care at this annual event. With its extensive ancillary program, numerous special events, two major congresses and the largest product display in the industry, MEDICA is the hub of the medical trade.
- On January 25, 2010, the Emergo Group will introduce the new Oxyview Nasal Cannula at Arab Health. The Arab Health Exhibition & Congress is the largest healthcare exhibition in the Middle East, and the second largest in the world. Arab Health is viewed as a must-attend global event in the healthcare calendar. Established 35 years ago, it provides a platform for the world’s leading manufacturers, wholesalers and distributors to meet the medical and scientific community in the Middle East and beyond.
- Mr. Sand refused to consider any reverse split now or in the future. Mr. Sand said that he is confident that the company cash reserve and increased revenues would support a share buy-back program for the shareholders. Mr. Sand further stated his concern with the past reverse splits, and he said that it would be unfair to the shareholders of this company to consider or effect any more reverse splits. Mr. Sand reminded the shareholders that he has converted his unpaid salary to shares over the past 5 years, and he was a shareholder as well who endured the greatest loss of personal capital with the reverse splits effected in the past.
- The designated Chinese patent application no. 200710005067.4 was officially issued and published on July 1, 2009 for the cannula gas flow meter referred to as “Oxyview”. The company’s pending patents in Japan, Canada, and the European Communities are expected to issue in 2010.
- As a part of improving product quality in large production, and reducing material and production costs to be more competitive in the respiratory marketplace, the company has received a proposal from a leading respiratory equipment manufacturer based in Pomona-California to manufacture both the Oxyview and the Oxyview Nasal Cannula at 50% of the original costs from its current manufacturer and supplier. “Now that we are selling our respiratory products, and sales have escalated, we must reduce our cost of goods sold in order to increase our profit margins and decrease the costs to our dealers and buyers. This change will give the company a stronger foot-hold in the market. We have a proprietary product and there is nothing in the marketplace that can compete with our device. We have gained support for all sectors of our industry, inclusive of leading respiratory equipment manufacturers, clinical foundations and more important, our shareholders,” stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.
- The Oxyview Nasal Cannula is available in various models for adult, pediatric and infant. Each age group can purchase the 0-6 liter/minute or the new “low flow” 0-3 liter/minute Oxyview Nasal Cannula. Included are discounts for purchasing the 10-Pack, 50-Pack or 100-Pack containers.